Omnipod 5 is the first CE marked tubeless automated insulin delivery (also known as hybrid closed loop) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System
The system is interoperable with Dexcom G6 for automated insulin delivery to help protect against high and low glucose levels . (Credit: Towfiqu barbhuiya on Unsplash)
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D) in its third market, Germany. Omnipod 5 is also available in the U.S. and the U.K.
“We know people in Germany living with type 1 diabetes want the most advanced technology options for making diabetes management easier,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “With our impressive data showing improved clinical outcomes from users in the United States over the past year, we are confident in our ability to make a difference in Germany and additional markets in the near future.”
Omnipod 5 is the first CE marked tubeless automated insulin delivery (also known as hybrid closed loop) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The system1 includes the tubeless Pod enhanced with SmartAdjust™ technology and a handheld Controller integrated with the SmartBolus Calculator. The system is interoperable with Dexcom G6 for automated insulin delivery to help protect against high and low glucose levels 2.
Laura Mysliwietz, a 29-year-old medical technologist, is beyond excited that Omnipod 5 is now available in her country. “Before I transitioned to Omnipod last year, I was using a traditional insulin pump, but the tubing was always in my way. Now, I sometimes forget that I have an insulin pump on my body,” said Laura. “Being tubeless makes my life so much easier, and the addition of an automated insulin delivery system will give me even more freedom to manage my type 1 diabetes. I can’t wait to use Omnipod 5!”
Insulet has presented real-world data from 36,634 adults3 and 18,516 children and adolescents4 with type 1 diabetes in the U.S. demonstrating that the highly favorable glycemic outcomes first reported in Omnipod 5 pivotal trials are achievable among Omnipod 5 users of all ages in the real world.
Omnipod 5 is now available in Germany and has received its medical aid numbers from the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), making it reimbursable by health insurers.
Source: Company Press Release